News Briefing channel feed – Endpoints News

News Briefing channel feed

Novartis throws Cerulean a lifeline with $5M deal; Porges disses Celgene’s GED-0301

9 years ago

New Vancouver-based fund has $100M to invest in biotech; FDA hands out $23M in rare disease R&D grants

9 years ago

Vertex snares $75M windfall in revised CFF deal; Ex-Celgene R&D prez Daniel starts advisory group

9 years ago

Flex Pharma's cramp study fails, shares plunge; FDA makes Egalet wait on pain drug

9 years ago

NeuroVive shares crater on PhII flop; F-Prime contributes $7.5M in startup cash for Akriveia

9 years ago

Leerink analyst adjusts nusinersen peak to $2.5B; Daiichi Sankyo signs up to work with Dana-Farber team

9 years ago

Auris tries to rebound from PhIII failure with new trial design; Kymab ties the knot with Shanghai-based EpimAb

9 years ago

#ESMO16: Boehringer drug flops on OS endpoint; Medivir reorganizes, cuts staff

9 years ago

Kite touts 12-month remission data from tiny CAR-T study; Ironwood exec dies in bike accident

9 years ago

Medicxi launches a diabetes upstart with $11M; Arrowhead partners on hep B; Immunotherapy startup gains $12.2M round

9 years ago

Biotech billionaire backs a food allergy/nutrition startup; Editas recruits a CMO

9 years ago

Samsung BioEpis pitches Herceptin biosimilar as parent company hunts $2B IPO; Chiasma CEO is out

9 years ago

Korean officials launch Hanmi probe in wake of tox reports; Prothena CEO Schenk dies

9 years ago

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

9 years ago

Catabasis shares rocket up on Duchenne pact with Sarepta; bluebird whistles up a TCR deal with Medigene

9 years ago

J&J hands Tracon two drugs, outlines buyback; Zymeworks does a cross-licensing deal with Daiichi Sankyo

9 years ago

Novartis vet O'Dowd takes the helm at Neon; FDA slaps a hold on Cel-Sci's PhIII cancer study

9 years ago

Idera dumps its lead cancer drug program; Pfizer won’t split up after all

9 years ago

Novartis preps Zykadia for a frontline NSCLC pitch, but faces a tough rival in Roche; J&J, GSK hustle RA drug sirukumab to the FDA

9 years ago

Zuckerberg-Chan win some respect for $3B biomedical project; AstraZeneca shutters another US office

9 years ago

Cytokine storms force Mirna to shutter a trial; Artios gathers $33M for cancer drug work

9 years ago

Alnylam will hire 100 for its new UK office; Puma shares surge as FDA accepts neratinib NDA

9 years ago

GE blueprints $165M biologics facilities; Tarveda to partner with Madrigal in $163M deal

9 years ago

Amgen partners with Genenta, San Raffaele on an anti-tumor drug

9 years ago

First page Previous page 75 76 777879 80 Next page Last page